Cefaclor advanced formulation 750 mg twice daily versus clarithromycin 500 mg twice daily in the treatment of acute maxillary sinusitis

Current Therapeutic Research - Clinical and Experimental

Volumn 60, Issue 4, 1999, Pages 185-194

  Bandak, Stephen ^a   Bolzon, Lynda ^a   Johns, Don ^a   Henle, Stacy ^a   Allen, Brad ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Acute maxillary sinusitis; Cefaclor AF; Clarithromycin

Indexed keywords

CEFACLOR; CLARITHROMYCIN;

ADULT; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXILLA SINUSITIS; PRIORITY JOURNAL; RASH; RHINORRHEA; TREATMENT OUTCOME;

EID: 0032918944     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)88514-8     Document Type: Article

References (14)

1. 1. Kaliner M, Osguthorpe J, Fireman P, et al. Bench to bedside. Otolaryngol Head Neck Surg. 1997;116(Suppl):S1-S20.
2. 2. Evans FO Jr, Sydnor JB, Moore WE, et al. Sinusitis of the maxillary antrum. NEJM. 1975;293:735-739.
3. 3. Gwaltney JM Jr, Scheld WN, Sande MA, et al. The microbial etiology and antimicrobial therapy of adults with acute community acquired sinusitis: A fifteen year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol. 1992;90:457-462.
4. 4. Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia (electronic version). Englewood, Colo: MICROMEDEX, Inc., 1996.
5. 5. Goumas P, Naxakis S, Bassaris C, Skoutelis A. Comparative efficacy and tolerability of clarithromycin and cefaclor in the treatment of outpatients with acute maxillary sinusitis. Clin Drug Invest. 1997;13:128-133.
6. 6. Stokes M, Davis C, Koch G. Categorical Data Analysis Using the SAS® System. Cary, NC: SAS Institute Inc.; 1995.
7. 7. Farrington C, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9:1447-1454.
8. 8. Williams J Jr, Holleman D Jr, Samsa G, Simel D. Randomized controlled trial 3 vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis. JAMA. 1995;273: 1015-1021.
9. 9. Clement P, De Gandt J. A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults. J Int Med Res. 1998;26: 66-75.
10. 10. Karma P, Pukander J, Penttila M, et al. The comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis. J Antimicrob Chemother. 1991;27(Suppl A):83-90.
11. 11. Sterkers O. Efficacy and tolerability of ceftibuten versus amoxicillin/clavulanate in the treatment of acute sinusitis. Chemotherapy. 1997;43:352-357.
12. 12. Zeckel M, Johns D, Masica D, Farlow D. Twice-daily dosing of loracarbef 200 mg versus 400 mg in the treatment of patients with acute maxillary sinusitis. Clin Ther. 1995;17: 214-230.
13. 13. Matthews B, Kohut R, Edelstein D, et al. Evaluation of cefixime in the treatment of bacterial maxillary sinusitis. South Med J. 1993;86:329-333.
14. 14. Casiano R. Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Am J Med. 1991;91:27S-30S.